Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000
Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000
复制标题
DOI：
10.1016/j.ijrobp.2006.07.1384
复制
发表时间：
2006-12-01
影响因子：
7
通讯作者：
Hayakawa, Kazushige
中科院分区：
文献类型：
--
作者：
Niibe, Yuzuru;Kenjo, Masahiro;Hayakawa, Kazushige
目的：大多数有任何癌症复发部位的患者被认为处于生命的最后阶段。然而，最近的临床研究进展显示，一些患者即使复发也能获得长期生存。此外，对于只有一个复发区域的患者，放射治疗可以发挥重要作用。至于子宫颈癌，除骨盆外，最常见的复发部位是腹主动脉旁淋巴结。因此，我们进行了目前的study.Patients和方法：在1994年和2003年之间，超过5,000名宫颈癌患者在13家日本医院进行了治疗。在这些患者中，84例发生了主动脉旁淋巴结复发，这是最初肿瘤进展的唯一部位。这些患者接受了外照射放射治疗。放疗方案为1.7-2.0戈伊/次，每周5次，平均总剂量50.8戈伊（25-60戈伊）。按症状分层，症状阳性组3年总生存率为27.6%，症状阴性组为56.1%（P = 0.018）。总剂量>= 51戈伊组和
Purpose: Most patients who had any recurrent sites of cancer have been considered to be in their last stage of life. However, recent advances of clinical research reveal some patients achieve long-term survival even in recurrence. Furthermore, for patients who had only one recurrent region, radiation therapy could play an important role. As for uterine cervical carcinoma, the most common recurrent site other than the pelvis is the para-aortic lymph nodes. Thus we conducted the current study.Patients and Methods: Between 1994 and 2003, more than 5,000 uterine cervical carcinoma patients were treated with curative-intended treatments at 13 Japanese hospitals. Of these patients, 84 developed para-aortic lymph node recurrence as the only site of initial tumor progression. These patients were treated with external beam radiation therapy. Radiation therapy protocol was as follows: 1.7-2.0 Gy per fraction, 5 fractions per week, and the mean total dose was 50.8 Gy (25-60 Gy).Results: Three- and 5-year overall survival rates of all patients were 49.5% and 31.3%, respectively. Stratified by symptom sign, 3-year overall survival rate of symptom positive was 27.6% and those of the negative was 56.1% (p = 0.018). Three-year overall survival rates of the total dose >= 51 Gy and that of